Physician profile
Megan Mccarthy
NPI 1619126067
$2,851.65
in general payments reported to CMS, 2019-2025
25 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $307 · 2021: $391 · 2022: $435 · 2023: $545 · 2024: $127 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.43 |
| Education | $287.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $732.19 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $557.86 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $219.82 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.74 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $141.84 | 2022-2023 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $128.57 | 2020-2025 | Abilify Asimtufii |
| Alkermes, INC. | $118.74 | 2019-2025 | Aristada, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $107.59 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.02 | 2020-2022 | |
| Astellas Pharma US INC | $86.34 | 2021 | |
| Sun Pharmaceutical Industries INC. | $79.99 | 2025 | |
| Neurocrine Biosciences, INC. | $74.97 | 2019-2024 | Ingrezza |
| Allergan, INC. | $69.17 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $40.34 | 2021 | |
| Almatica Pharma LLC | $34.44 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $29.95 | 2024 | Auvelity |
| Indivior INC. | $28.57 | 2023 | Perseris |
| Vanda Pharmaceuticals INC. | $27.21 | 2025 | Fanapt |
| Lilly USA, LLC | $18.05 | 2019 | |
| Acadia Pharmaceuticals INC | $17.11 | 2022 | |
| Lundbeck LLC | $15.80 | 2020 | |
| Corium, LLC | $15.49 | 2024 | Azstarys |
| Shire North American Group INC | $15.40 | 2019 | |
| Alfasigma USA, INC. | $14.75 | 2020 | |
| Sage Therapeutics, LLC | $14.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.